TBPHHealthcare · BiotechnologyThe 5 Wall Street analysts covering Theravance Biopharma, Inc. hold a median 12-month price target of $17 — -0.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 12 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Theravance Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TBPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −0.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | $15 → $17 |
| 29 June 2026 | BTIG | Downgrade | Neutral | — |
| 29 June 2026 | Jones Trading | Downgrade | Hold | — |
| 7 Apr 2026 | B. Riley Securities | Maintains | Neutral | — |
| 23 Mar 2026 | TD Cowen | Maintains | Hold | — |
| 20 Mar 2026 | BTIG | Reiterates | Buy | — |
| 5 Mar 2026 | Oppenheimer | Downgrade | Perform | — |
| 4 Mar 2026 | B. Riley Securities | Downgrade | Neutral | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Feb 2026 | BTIG | Reiterates | Buy | — |
| 3 Dec 2025 | Oppenheimer | Initiates | Outperform | — |
| 26 Nov 2025 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Sept 2025 | B. Riley Securities | Initiates | Buy | — |
| 27 June 2025 | BTIG | Maintains | Buy | — |
| 17 June 2025 | Jones Trading | Initiates | Buy | — |
| 27 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TBPH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Theravance Biopharma, Inc. returned +24.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 16% of US stocks
Cheaper than 32% of US stocks
Cheaper than 5% of US stocks
Higher than 11% of US stocks
Higher than 20% of US stocks
Higher than 62% of US stocks
Higher than 96% of US stocks
Higher than 82% of US stocks
Higher than 53% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Theravance Biopharma, Inc. has a market value of $883.1M and an enterprise value of $534.1M.
Revenue in the twelve months to 30 June 2026: $104.3M. The latest quarter shrank 20.9% year on year.
Net income over the same four quarters: $53.8M, a 51.6% net margin.
Diluted earnings per share, trailing twelve months: $1.01.
Free cash flow in the twelve months to 30 June 2026: $53.7M.
Theravance Biopharma, Inc. spent $10.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 16.4×; forward P/E: 13.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Theravance Biopharma, Inc. employs 90 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Theravance Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Theravance Biopharma reported earnings 30 days ago, and its stock has risen 0.8% since that report. The article examines what may be next for the stock following that earnings release.
Why it matters — TBPH watchers would be interested in the stock's post-earnings performance and the outlook following the company's latest quarterly report.
Investor rights law firm Halper Sadeh LLC has opened an investigation into the sale of Theravance Biopharma to Zymeworks Inc. for $17.00 per share. The firm is examining whether Theravance and its board of directors violated their obligations in obtaining a fair price for shareholders, and is encouraging shareholders to learn about their rights.
Why it matters — TBPH watchers would care because the announcement raises questions about the fairness of the proposed acquisition price received by existing shareholders.
Theravance Biopharma reported second-quarter earnings that matched analyst estimates. The company has also agreed to be acquired by Zymeworks in a $929 million deal, following cost cuts and the discontinuation of ampreloxetine.
Why it matters — TBPH watchers would care because the acquisition by Zymeworks marks a significant corporate change for the company following its earnings report and pipeline setback.
Theravance Biopharma reported second quarter 2026 financial results, noting YUPELRI collaboration revenue rose 11% year-over-year to $20.7 million, a 35% reduction in operating expenses from restructuring and cost initiatives, a quarter-end cash balance of $388 million with no debt, and high confidence in achieving the $100 million 2026 milestone payment tied to TRELEGY net sales of approximately $1.0 billion. The company also reiterated that its previously announced acquisition by Zymeworks is expected to close in the second half of 2026.
Why it matters — TBPH watchers would care because the results highlight revenue growth, reduced expenses, a strong debt-free cash position, and progress toward the Zymeworks acquisition that resulted from the strategic review.
The 5 Wall Street analysts covering Theravance Biopharma, Inc. have a median 12-month price target of $17, with estimates ranging from $17 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Theravance Biopharma, Inc., 0 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Theravance Biopharma, Inc. 89 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Theravance Biopharma, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies -0.1% from the last close, and Ticker Nerd's factor model ranks Theravance Biopharma, Inc. 89 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Theravance Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TBPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $19 over the next 12 months.
Theravance Biopharma, Inc. returned +24.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Theravance Biopharma Inc. is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and selected specialized conditions.
The most recent item we track (Zacks Investment Research, 9 Sept 2026): "Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?". Theravance Biopharma reported earnings 30 days ago, and its stock has risen 0.8% since that report. The article examines what may be next for the stock following that earnings release.
Theravance Biopharma Inc. is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and selected specialized conditions. Its commercial portfolio is centered on YUPELRI, an inhaled therapy used in chronic obstructive pulmonary disease (COPD), supported by a broader respiratory franchise that addresses patient needs in outpatient and clinical care settings. The company also pursues medicines for rare and complex disorders, including ampreloxetine, an investigational therapy studied for symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy. Theravance Biopharma Inc. works across research, clinical development, and product commercialization, giving it a role in advancing treatments from late-stage development to market access. Based in South San Francisco, California, the company operates as a focused healthcare business serving physicians, patients, and healthcare systems with therapies designed for chronic management and specialty care.
CEO Mr. Rick E. Winningham M.B.A. · 90 employees · United States · https://www.theravance.com
